Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial

Savannah C. Partridge, PhD • Zheng Zhang, PhD • David C. Newitt, PhD • Jessica E. Gibbs, BA • Thomas L. Chenevert, PhD • Mark A. Rosen, MD, PhD • Patrick J. Bolan, PhD • Helga S. Marques, MA • Justin Romanoff, MA • Lisa Cimino, RT • Bonnie N. Joe, MD, PhD • Heidi R. Umphrey, MD • Haydee Ojeda-Fournier, MD • Basak Dogan, MD • Karen Oh, MD • Hiroyuki Abe, MD, PhD • Jennifer S. Drukeiuns, MD • Laura J. Esserman, MD, MBA • Nola M. Hylton, PhD, For the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators

From the Department of Radiology, University of Washington, 825 Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics (Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.); Brown University, Providence, RI; American College of Radiology Imaging Network (ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N., J.E.G., B.N.I., L.J.E., N.M.H.); Department of Radiology/MRI, University of Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn (P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group, Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham, Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and Science University, Portland, Ore (K.O.); Department of Radiology, University of Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.).

Received February 8, 2018; revision requested March 28; final revision received July 12; accepted July 18. Address correspondence to S.C.P. (e-mail: scp3@uw.edu).

Supported by the National Cancer Institute through grants U01 CA079778 and U01 CA080098 (to the American College of Radiology Imaging Network), grant R01 CA151326 (to S.C.P.), grant U01 CA166104 (to T.L.C.), grant P41 EB015894 (to P.J.B.), and grants U01 CA151235 and R01 CA132870 (to N.M.H.).

Conflicts of interest are listed at the end of this article. See also the editorial by deSouza in this issue.

Purpose: To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer.

Materials and Methods: In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype.

Results: The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR+/HER2+ disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR+/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032).

Conclusion: After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy.

© RSNA, 2018

Online supplemental material is available for this article.

Diffusion-weighted (DW) MRI, a functional imaging technique reflecting water diffusion properties in tissue, holds strong potential to reveal early pathologic changes in tumors responding to therapy. Specifically, the apparent diffusion coefficient (ADC) measured at DW MRI, which reflects cellularity and interstitial water mobility, has shown promise as an imaging biomarker to measure early tumor response to treatment (1). Cytotoxic effects of chemotherapy cause cell lysis, alterations in cell membrane permeability, and increases in extracellular space, which lead to a less restrictive environment for water to diffuse. Therefore, it has been hypothesized that an increase in tumor ADCs may reflect favorable treatment response earlier than detectable changes in tumor size.

Change in tumor ADC with treatment has been investigated in a variety of malignancies, including breast cancer (2). Results of prior studies have demonstrated that breast tumor ADCs can significantly differentiate patients who respond to treatment from those who do not (3–5) and predict pathologic response (6–9). However, reports have
Abbreviations
ACRIN = American College of Radiology Imaging Network, ADC = apparent diffusion coefficient, AUC = area under the receiver operating characteristic curve, CI = confidence interval, DCE = dynamic contrast enhanced, DW = diffusion weighted, FDA = Food and Drug Administration, HER2 = human epidermal growth factor receptor 2, HR = hormone receptor, I-SPY 2 = Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2, pCR = pathologic complete response, ROI = region of interest

Summary
Change in apparent diffusion coefficient at diffusion-weighted MRI after 12 weeks of therapy is a noninvasive and quantitative imaging biomarker of response in women undergoing neoadjuvant chemotherapy for breast cancer.

Implications for Patient Care
- Diffusion-weighted MRI depicts the cytotoxic effects of chemotherapy in breast tumors.
- Greater increases in tumor apparent diffusion coefficient after 12 weeks of chemotherapy predict pathologic response and higher likelihood of pathologic complete response.
- Diffusion-weighted MRI may enable objective assessment of therapeutic efficacy, particularly for hormone receptor-positive, human epidermal growth factor receptor 2-negative disease.

Materials and Methods
Subject Eligibility and Enrollment
In this prospective Health Insurance Portability and Accountability Act–compliant multi-institution study, consecutive subjects who were enrolled in I-SPY 2 at sites that met DW MRI qualification requirements were also co-enrolled in the ACRIN 6698 imaging trial (ClinicalTrials.gov: NCT01564368 [14]). Patients eligible for I-SPY 2 included women 18 years of age or older with invasive breast tumors 2.5 cm or larger at clinical examination or imaging who were planning to undergo neoadjuvant chemotherapy. Patients with evidence of distant metastasis were excluded, and those found to have low-risk disease did not proceed to the treatment arm of I-SPY 2. Low-risk disease was defined as hormone receptor (HR)-positive (hereafter, HR+)/human epidermal growth factor receptor 2 (HER2)-negative (hereafter, HER2-) disease or disease with a low-risk profile at MammaPrint testing (Agenda; Irvine, Calif). Both the I-SPY 2 and ACRIN 6698 protocols were approved by institutional review boards at all participating sites, and all subjects gave written informed consent by using a single combined consent form. Six patients in our study overlapped with those of two prior I-SPY 2 trial publications reporting promising efficacy of supplemental neratinib and veliparib-carboplatin treatments in select cancer subtypes (15,16).

MRI examinations with DW MRI were performed before treatment, during early treatment (after three weekly doses of paclitaxel/taxane-based therapy), at midtreatment (12 weeks, between taxane and anthracycline regimens), and after treatment after all chemotherapy, prior to surgery. Our study schema is shown in Figure 1a.

Site Qualification
Each MRI system used in the ACRIN 6698 study was required to pass a DW MRI qualification process incorporating assessment of both phantom and patient studies, as described in detail in Appendix E1 (online).

MRI Acquisition
MRI was performed by using a 1.5- or 3.0-T field strength magnet and a dedicated breast radiofrequency coil. The standardized image acquisition protocol included T2-weighted, DW, and DCE MRI sequences performed bilaterally in the axial orientation (18); imaging parameters for each sequence are provided in Table E1 (online). DW MRI was performed before DCE MRI by using a DW single-shot echo planar imaging sequence with parallel imaging (reduction factor, two or greater); fat suppression; a repetition time of greater than 4000 msec; echo time minimum; flip angle, 90°; field of view, 300–360 mm; acquired matrix, 128 × 128 to 192 × 192; in-plane resolution, 1.7–2.8 mm; section thickness, 4–5 mm; and imaging time, 5 or fewer minutes. Diffusion gradients were applied in three orthogonal directions by using diffusion weightings (b values) of 0, 100, 600, and 800 sec/mm². No respiratory triggering or other motion compensation methods were used. T2-weighted imaging was performed by using a two-dimensional fast spin-echo or a short inversion time inversion recovery sequence (repetition time msec/echo time msec, 2000–10 000/70–140; flip angle, 90°; in-plane resolution, ≤1.4 mm; section thickness, ≤4 mm; gap, ≤1 mm; and imaging time, ≤7 minutes). DCE MRI was performed by using a three-dimensional fat-suppressed T1-weighted gradient-echo sequence with the following parameters: repetition time,
whole-tumor regions of interest (ROIs) were manually defined by selecting regions with hyperintensity at high-\textit{b}-value DWI (\(b = 600\) or 800 sec/mm\(^2\)) and relatively low ADC while avoiding adjacent adipose and fibroglandular tissue, biopsy clip artifacts, and regions of high T2 signal (eg, seroma and necrosis). For large and multicentric or multifocal disease, all disease regions were included in the ROI, and several distinct contours could be drawn on multiple sections to cover the entire tumor region as depicted on the DCE images, without including intervening stroma (Fig E1 [online]). All voxels from separate contours were then combined into a single composite ROI to represent the entire tumor, and the mean ADC was calculated. Tumor ROIs were redefined for each treatment time point, referencing lesion location on prior examinations. In tumors without residual enhancement at DCE MRI after treatment, ROIs were defined in the same tissue region as the prior examination.

Per the I-SPY 2 trial protocol, FTV at DCE MRI was prospectively calculated at each treatment time point by site investigators, blinded to pathologic outcomes, using semi-automated U.S. Food and Drug Administration (FDA) investigational device exemption–approved software (Aegis; Hologic, Danbury, Conn). FTV is a previously established predictive imaging marker reflecting tumor vascularity (21,22) used in I-SPY 2 to adjust randomization and evaluate response. As previously described (22), FTV (in cubic centimeters) was computed by summing all tumor voxels meeting specific enhancement criteria, with customized thresholds for each site to account for variability in MRI systems. The

4–10 msec; echo time, minimum; flip angle, 10–20°; in-plane resolution, \(\leq 1.4\) mm; section thickness, \(\leq 2.5\) mm; and imaging time, 80–100 seconds. Multiple sequential phases were acquired: one before and five or more (for at least 8 minutes) after intravenous gadolinium-based contrast material injection (0.1 mmol per kilogram of body weight at 2 mL/sec, followed by a 20-mL saline flush). The study protocol did not specify the gadolinium agent to be used, but required that the same agent be used for all MRI examinations for an individual patient.

**Image Analysis**

Centralized DW MRI analysis was performed by trained researchers at University of California, San Francisco, who were blinded to pathologic outcomes (final review performed by J.E.G., with more than 10 years of quantitative breast MR analysis experience), using custom software tools developed with IDL (Exelis Visual Information Solutions, Boulder, Colo). ADC parametric maps (in square millimeters per second) were created by using a linear least-squares fit of the log of the signal intensities at all four \(b\) values (0, 100, 600, and 800 sec/mm\(^2\)) and a classic monoexponential decay model (19), as follows:

\[
S(b) = S_0 \times e^{-b \cdot \text{ADC}},
\]

where \(S(b)\) is the signal intensity with diffusion weighting \(b\) and \(S_0\) is the signal with no diffusion weighting (20).

Tumors were identified on postcontrast DCE subtraction images and were then localized on DW MR images. Multisection
chemistry or other methods according to the I-SPY 2 trial protocol (17). Tumor subtypes were categorized as HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2- (triple negative).

**Statistical Analysis**

ACRIN 6698 was powered to enroll 160 evaluable subjects to adequately test whether changes in tumor ADC during treatment were predictive of pCR (18). Tumor ADC change, calculated as the percentage change from the pretreatment value (\(\Delta ADC\)), was evaluated at each treatment time point. Receiver operating characteristic curves and the areas under the receiver operating characteristic curve (AUCs) were estimated empirically, and the 95% confidence interval (CI) of the estimated AUC was constructed by using variance derived from the DeLong method (25). The empirical AUC was tested by using the Z-test to determine if the AUC was at least 0.5. Exploratory analyses were also performed according to tumor subtype. The Bonferroni correction was used for multiple comparisons of \(\Delta ADC\): for all lesions and by tumor subtype across three treatment time points (early, middle, and post), where \(P < 0.003 (.05/15)\) was considered to indicate a statistically significant difference. To build prediction models with ADC and other variables, a data-splitting approach was used where a randomly selected 60% of participants, stratified according to pCR status and tumor subtype, were selected as the training data set and the rest as the test set. Logistic regression with backward variable selection was used to construct the prediction models, which were then applied to the remaining 40% of the data to obtain predictive scores for each participant. Receiver operating characteristic curves were constructed for the predictive scores to predict pCR, and the corresponding AUCs and 95% CIs were calculated. Statistical analyses were performed by using SAS/STAT software, version 9.4 (SAS Institute, Cary, NC), and R, version 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

A total of 406 consecutive patients were enrolled in the ACRIN 6698 trial at 10 institutions, including patients from...
all treatment arms active during the period of enrollment from August 2012 to January 2015. Eighteen (4.4%) of 406 patients were found to be ineligible for I-SPY 2; 116 patients (30%) were not randomized to treatment (factors included MammaPrint low-risk disease, tissue sample and/or microarray issues precluding MammaPrint determination, and patient withdrawal) and 30 patients (7.7%) were excluded because of missing or nonevaluable or poor-quality DW MRI studies (Fig 1b). Of the remaining 242 participants comprising the analysis set, 227 (94%) had evaluable imaging studies at early treatment/3 weeks, 210 (87%) at midtreatment/12 weeks, and 186 (77%) after treatment. Patient characteristics were comparable for the eligible (n = 388) and analysis set (n = 242) groups (Table 1). In the 242 evaluable patients, the mean age was 48 years ± 10. The majority of participants had grade III breast cancer (168 [69%] of 242) and either HR+/HER2- (99 [41%] of 242) or HR-/HER2- (triple negative) (77 [32%] of 242) subtypes (Table 1). After treatment, 80 (33%) of the 242 patients experienced pCR. Multiple MRI vendor systems were represented, and the majority of the patients (169 [70%] of 242) were imaged at 1.5 T (Table E2 [online]).

**Association of ADC with Pathologic Response**

Mean tumor ADCs (×10⁻³ mm²/sec) were 1.08 ± 0.20, 1.24 ± 0.27, 1.48 ± 0.42, and 1.62 ± 0.41 at pretreatment, early-treatment (3 weeks), midtreatment (12 weeks), and posttreatment time points, respectively, suggesting a generally increasing trend as treatment progressed. Examples of serial DW MRI quantification in study patients exhibiting different responses to treatment are shown in Figures 2 and 3. No differences were observed in pretreatment ADC between patients with pCR and those without pCR (mean, 1.08 ± 0.16 and 1.08 ± 0.22, respectively), but differences in ADC response were evident during treatment (Fig 4a). ∆ADC was not predictive of pCR at early treatment/3 weeks (AUC = 0.53; 95% CI: 0.45, 0.61; P = .48). By midtreatment/12 weeks, mean ∆ADC was greater in patients with pCR than in patients without pCR (50% ± 49 and 36% ± 44, respectively) and was predictive of pCR, with AUC = 0.60 (95% CI: 0.52, 0.68; P = .017). ∆ADC at posttreatment was similarly predictive, with AUC = 0.61 (95% CI: 0.52, 0.69, P = .013) (Table 2), although neither ∆ADC at midtreatment nor ∆ADC at posttreatment was significant after multiple-comparison adjustment.

**Influence of Lesion Subtype on Predictive Value of ADC Measures**

Because mechanisms of treatment response vary with underlying tumor biology, the predictive value of ADC was explored in post-hoc analysis by HR/HER2 subtype. The time course of tumor ADC response differed somewhat across tumor subtypes (Fig 4b), as well as between patients with and those without pCR within each subtype (Fig E2 [online]). HR+/HER2- tumors (the most common subtype) demonstrated the lowest pCR rate (15 [15%] of 99), while HR-/HER2+ tumors (the least common
trials. By tumor subtype, ∆FTV was predictive only in HR+/HER2- tumors (at all time points; AUCs = 0.69–0.70) and triple-negative (HR-/HER2-) tumors (at posttreatment only, AUC = 0.74; 95% CI: 0.62, 0.86)—similar results to those of ∆ADC (Table E3 [online]).

Predictive Modeling for Pathologic Response

We next sought to construct a predictive model using ADC, tumor subtype, and FTV to improve performance for predicting pCR. Predictive logistic regression modeling was performed in 207 patients with complete midtreatment ∆ADC and ∆FTV data. The data were split into a 60% training set (124 patients, randomly selected and stratified according to tumor subtype) and a 40% validation set (86 patients).

Characteristics of the 86-patient test set were representative of the full analysis set, with a mean age of 48 years ± 11; 35 patients (41%) had HR+/HER2- disease, 27 (31%) had HR-/HER2- disease, 15 (17%) had HR+/HER2+ disease, and nine (11%) had HR-/HER2+ disease; 29 (34%) of the 86 patients achieved pCR. A model combining ADC, FTV, and cancer subtype resulted in an overall predictive performance of AUC = 0.71 (95% CI: 0.59, 0.84). After employing the backward selection algorithm, FTV was eliminated, and the final prediction model retained ADC and tumor subtype as predictors. The final model with ADC and tumor subtype was significantly more predictive of pCR (AUC = 0.72; 95% CI: 0.61, 0.83) than was ADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032) in the same test set (Fig 6).

Discussion

Results of the multicenter ACRIN 6698 trial demonstrate that change in tumor ADC at DW MRI after 12 weeks of therapy is a noninvasive and quantitative imaging biomarker of response in women undergoing neoadjuvant chemotherapy for breast cancer. Our study found that midtreatment ∆ADC, ∆FTV, and cancer subtype resulted in an overall predictive performance of AUC = 0.71 (95% CI: 0.59, 0.84). After employing the backward selection algorithm, ∆FTV was eliminated, and the final prediction model retained ∆ADC and tumor subtype as predictors. The final model with ∆ADC and tumor subtype was significantly more predictive of pCR (AUC = 0.72; 95% CI: 0.61, 0.83) than was ∆ADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032) in the same test set (Fig 6).

Association of FTV with Pathologic Response

Overall, ∆FTV was predictive of pCR (P < .001) at each time point, with AUCs ranging from 0.63 to 0.68 (Table 4). Greater decreases in FTV predicted pCR, as has been reported in prior trials. By tumor subtype, ∆FTV was predictive only in HR+/HER2- tumors (at all time points; AUCs = 0.69–0.70) and triple-negative (HR-/HER2-) tumors (at posttreatment only, AUC = 0.74; 95% CI: 0.62, 0.86)—similar results to those of ∆ADC (Table E3 [online]).

Figure 3: Serial diffusion-weighted (DW) MR images in a 51-year-old woman who underwent neoadjuvant treatment for grade III hormone receptor–positive/human epidermal growth factor receptor 2–negative cancer and who had residual disease at surgery (and thus did not experience pathologic complete response). Imaging was performed with a 3.0-T MRI unit. Shown are axial postcontrast dynamic contrast-enhanced (DCE) MRI images (left), noncontrast DW MRI (b = 800 sec/mm²) images (center), and apparent diffusion coefficient (ADC) maps (right). At each time point, a whole-tumor region of interest (ROI) was defined across multiple sections at DW MRI, and mean ADC was calculated for all voxels in the composite ROI. The tumor appeared as a 7.5-cm mass at pretreatment DCE MRI (top). Serial ADC measures increased only slightly with treatment, with ∆ADC = 9.5% at early treatment/3 weeks, 14% at midtreatment/12 weeks, and 29% at posttreatment.
Exploratory analysis suggested higher predictive performance of ∆ADC in HR-positive, HER2-negative tumors. This may have special clinical importance, as HR+/HER2- tumors are less likely to shrink in response to chemotherapy and less often achieve pCR (26), while residual disease is also more commonly underestimated at DCE MRI in HR+/HER2- tumors (26,27). While the primary aim of the ACRIN 6698 trial was to evaluate the performance of ADC alone as a predictor of pCR, multiparametric MRI approaches hold promise to enhance sensitivity for detecting response (7). Our findings showed that the predictive value of ADC may be comparable to or higher than that of DCE MRI–derived FTV for midtreatment response prediction (particularly in HR+/HER2- disease), but the combination of ADC and FTV may not further improve overall predictive accuracy. Although the ADC measurements were not fully independent of the contrast-enhanced images (the ROIs were drawn using the postcontrast images for guidance), these results suggest that DW MRI may have a role as a noncontrast alternative to DCE MRI. This could enable more frequent monitoring of response without the time, costs, and toxicities associated with administration of gadolinium-based contrast material, but additional studies would be required to evaluate the relative advantages of ADC and FTV. It is also important to note that our study was not powered for subgroup analysis, and the failure to detect ∆ADC as a significant predictor of pCR in the three tumor subtypes other than HR+/HER2- may be due to inadequate statistical power in these smaller subgroups.

Our study supports results from multiple single-site studies reporting greater treatment-induced increases in tumor ADCs in responders versus nonresponders (3–5,28–30). This increase in tumor ADC is thought to reflect reduced cell membrane integrity and reduced cellularity due to effective cytotoxic chemotherapy, resulting in a less restrictive environment for diffusing water molecules. While several prior studies reported changes in ADC to be predictive after the first cycle of chemotherapy (3–5,7), we did not observe a difference between responders and nonresponders until midtreatment, after 12 weekly cycles of paclitaxel-based therapy. Exclusion of patients with low-risk HR+/HER2- disease in I-SPY 2 may partially explain differences in our results versus those of prior studies, because ADC was most predictive in this subtype. Another important consideration is the variety of treatment regimens comprising the ACRIN 6698 trial data. Patients were randomized to one of multiple experimental treatment arms. Because of the adaptive I-SPY 2 study design, it was not possible to power ACRIN 6698 to control for varying therapies. However, because mechanisms of action differ across treatments, stratification by treatment regimen may yield more insights on the relative value of DW MRI versus DCE MRI and optimal timing for assessing treatment efficacy.

**Table 2: Performance of Tumor ∆ADC for Predicting pCR at Each Treatment Time Point**

<table>
<thead>
<tr>
<th>Treatment Time Point</th>
<th>Patients with pCR</th>
<th>Patients without pCR</th>
<th>95% Confidence Interval</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Mean ∆ADC ± Standard Deviation (%)</td>
<td>No. of Patients</td>
<td>Mean ∆ADC ± Standard Deviation (%)</td>
</tr>
<tr>
<td>Early treatment/3 weeks</td>
<td>71</td>
<td>18 ± 20</td>
<td>156</td>
<td>16 ± 21</td>
</tr>
<tr>
<td>Midtreatment/12 weeks</td>
<td>70</td>
<td>50 ± 49</td>
<td>140</td>
<td>36 ± 44</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>63</td>
<td>64 ± 49</td>
<td>123</td>
<td>50 ± 47</td>
</tr>
</tbody>
</table>

Note.—AUC = area under the receiver operating characteristic curve, ∆ADC = change in tumor apparent diffusion coefficient (from pretreatment value), pCR = pathologic complete response.

* Significant at P < .05, but not after multiple-comparison adjustment (P < .003).
manufacturers, field strengths, and capabilities) further led to variable image quality. Differences in manufacturer approaches to image reconstruction, scaling, and system-generated ADC maps must also be taken into account, as these differences necessitated additional centralized postprocessing steps before the intersite data were pooled in our study. Many of these limitations are being addressed by MRI system manufacturers and will hopefully lead to greater accuracy and reproducibility of breast DW MRI.

Our study had limitations. ADC was calculated by using a conventional monoexponential decay model with \( b \) values ranging from 0 to 1000 s/mm\(^2\).

<table>
<thead>
<tr>
<th>Table 3: Performance of Tumor ( \Delta \text{ADC} ) for Predicting pCR Stratified by Cancer Subtype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Subtype and Treatment Time Point</td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>HR-/HER2- Early treatment/3 weeks</td>
</tr>
<tr>
<td>HR-/HER2- Midtreatment/12 weeks</td>
</tr>
<tr>
<td>HR-/HER2- Posttreatment</td>
</tr>
<tr>
<td>HR+/HER2- Early treatment/3 weeks</td>
</tr>
<tr>
<td>HR+/HER2- Midtreatment/12 weeks</td>
</tr>
<tr>
<td>HR+/HER2- Posttreatment</td>
</tr>
<tr>
<td>HR-/HER2+ Early treatment/3 weeks</td>
</tr>
<tr>
<td>HR-/HER2+ Midtreatment/12 weeks</td>
</tr>
<tr>
<td>HR-/HER2+ Posttreatment</td>
</tr>
<tr>
<td>HR+/HER2+ Early treatment/3 weeks</td>
</tr>
<tr>
<td>HR+/HER2+ Midtreatment/12 weeks</td>
</tr>
<tr>
<td>HR+/HER2+ Posttreatment</td>
</tr>
</tbody>
</table>

Note.—AUC = area under the receiver operating characteristic curve, \( \Delta \text{ADC} \) = change in tumor apparent diffusion coefficient (from pretreatment value), HER2 = human epidermal growth factor receptor 2, HR = hormone receptor, pCR = pathologic complete response. * Significant after multiple-comparison adjustment \( (P < 0.003) \).

**Figure 5**: Receiver operating characteristic curves for predicting pathologic complete response on the basis of percentage change in tumor apparent diffusion coefficient, stratified by tumor subtype. Curves and calculated areas under the curves are shown with 95% confidence intervals at (a) early treatment/3 weeks, (b) midtreatment/12 weeks, and (c) posttreatment/presurgery time points. HR = hormone receptor, HER2 = human epidermal growth factor receptor 2.
from 0 to 800 sec/mm², which likely included contributions from microvasculature (more prominent at low b values < 200 sec/mm²) and limited the sensitivity for identifying microstructural changes. Advanced DW MRI modeling techniques may better depict therapeutic effects, including intravoxel incoherent motion modeling to additionally quantify perfusion and kurtosis or stretched-exponential modeling to assess microstructural alterations in breast tumors. Although DW MRI and DCE MRI characterize different and potentially independent prognostic biologic properties related to tumor proliferation and angiogenesis, respectively, our preliminary findings did not confirm them to be complementary in predicting pCR. Further investigation is warranted to assess the potential role of DW MRI as a noncontrast alternative to DCE MRI for midtreatment assessment of therapeutic efficacy. More detailed evaluation of ACRIN 6698 trial data regarding specific therapies, alternate analytic approaches, and optimal assessment timing will likely yield additional value of DW MRI for monitoring therapy and further clarify the role of DW MRI as a quantitative imaging marker of response in breast cancer clinical trials and personalized treatment regimens.

**Acknowledgments:** The authors acknowledge those individuals who have contributed substantially to the work reported in the manuscript, including the ACRIN 6698 and I-SPY 2 trial teams, the patients who participated in the study, and the staff members who contributed to the conduct of the study at the University of California, San Francisco; University of Minnesota; University of Pennsylvania; University of Washington; University of Alabama, Birmingham; University of California, San Diego; University of Texas MD Anderson Cancer Center; Oregon Health Sciences University; University of Chicago; and H. Lee Moffitt Cancer Center and Research Institute.

**Author contributions:** Guarantors of integrity of entire study, S.C.P., N.M.H.; study concept and design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; manuscript final version approval, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, S.C.P., B.J.N., N.M.H.; clinical studies, S.C.P., D.C.N., J.E.G., M.A.R., P.J.B., H.S.M., J.R., B.N.J., H.O., B.D., K.O., J.S.D., L.J.E., N.M.H.; experimental studies, T.L.C., B.N.J., H.O., J.S.D., N.M.H.; statistical analysis, S.C.P., Z.Z., D.C.N., J.E.G., T.L.C., M.A.R., P.J.B., H.S.M., J.R., B.N.J., H.R.U., H.O., B.D., K.O., J.S.D., L.J.E., N.M.H.

**Disclosures of Conflicts of Interest:** S.C.P. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: institution has received funding from GE Healthcare and Philips Healthcare; institution has received in-kind research support for an advanced MRI study. Other relationships: disclosed no relevant relationships. Z.Z., disclosed no relevant relationships. D.C.N., disclosed no relevant relationships. J.E.G., disclosed no relevant relationships.


